TG Therapeutics announces Orphan Drug Designation for TG-1101
TG Therapeutics announced the FDA has granted orphan drug designation for TG-1101 (ublituximab) the Company's novel, glycoengineered anti-CD20 monoclonal antibody, for treatment of patients with neuromyelitis optica and neuromyelitis optica spectrum disorder. August 26, 2016